rolipram

Summary

Summary: A phosphodiesterase inhibitor with antidepressant properties.

Top Publications

  1. pmc Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment
    Bing Gong
    The Center for Dementia Research, Nathan Kline Institute for Psychiatric Research, Orangeburg, New York, USA
    J Clin Invest 114:1624-34. 2004
  2. pmc Downregulation of brain phosphodiesterase type IV measured with 11C-(R)-rolipram positron emission tomography in major depressive disorder
    Masahiro Fujita
    Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892 1026, USA
    Biol Psychiatry 72:548-54. 2012
  3. ncbi Differential effects of rolipram on chronic subcutaneous inflammatory angiogenesis and on peritoneal adhesion in mice
    Juliana B Mendes
    Departments of Physiology and Biophysics and General Pathology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil
    Microvasc Res 78:265-71. 2009
  4. ncbi Inhibitor binding to type 4 phosphodiesterase (PDE4) assessed using [3H]piclamilast and [3H]rolipram
    Yu Zhao
    Department of Pharmacology, University of Tennessee Health Science Center, 874 Union Avenue, Memphis, TN 38163, USA
    J Pharmacol Exp Ther 305:565-72. 2003
  5. pmc Kinetic analysis in human brain of [11C](R)-rolipram, a positron emission tomographic radioligand to image phosphodiesterase 4: a retest study and use of an image-derived input function
    Paolo Zanotti-Fregonara
    Molecular Imaging Branch, National Institute of Mental Health, Bethesda, Maryland 20892 2035, USA
    Neuroimage 54:1903-9. 2011
  6. pmc Antidepressant- and anxiolytic-like effects of the phosphodiesterase-4 inhibitor rolipram on behavior depend on cyclic AMP response element binding protein-mediated neurogenesis in the hippocampus
    Yun Feng Li
    Department of Behavioral Medicine and Psychiatry, West Virginia University Health Sciences Center, Morgantown, WV 26506 9137, USA
    Neuropsychopharmacology 34:2404-19. 2009
  7. ncbi Effects of combining methylprednisolone with rolipram on functional recovery in adult rats following spinal cord injury
    Ying Yin
    Department of Clinical Laboratory Science, Wuxi People s Hospital of Nanjing Medical University, Wuxi, PR China
    Neurochem Int 62:903-12. 2013
  8. pmc Image-derived input function for human brain using high resolution PET imaging with [C](R)-rolipram and [C]PBR28
    Paolo Zanotti-Fregonara
    Molecular Imaging Branch, National Institute of Mental Health NIMH, National Institutes of Health NIH, Bethesda, Maryland, United States of America
    PLoS ONE 6:e17056. 2011
  9. ncbi Regulation of neurogenesis in adult mouse hippocampus by cAMP and the cAMP response element-binding protein
    Shin Nakagawa
    Division of Molecular Psychiatry, Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, Yale University School of Medicine, New Haven, Connecticut 06508, USA
    J Neurosci 22:3673-82. 2002
  10. ncbi The phosphodiesterase-4 (PDE4) inhibitor rolipram decreases ethanol seeking and consumption in alcohol-preferring Fawn-Hooded rats
    Rui Ting Wen
    National Institute on Drug Dependence, Peking University, Beijing, China
    Alcohol Clin Exp Res 36:2157-67. 2012

Detail Information

Publications281 found, 100 shown here

  1. pmc Persistent improvement in synaptic and cognitive functions in an Alzheimer mouse model after rolipram treatment
    Bing Gong
    The Center for Dementia Research, Nathan Kline Institute for Psychiatric Research, Orangeburg, New York, USA
    J Clin Invest 114:1624-34. 2004
    ..Here we demonstrate that brief treatment with the phosphodiesterase 4 inhibitor rolipram ameliorates deficits in both long-term potentiation (LTP) and contextual learning in the double-transgenic mice...
  2. pmc Downregulation of brain phosphodiesterase type IV measured with 11C-(R)-rolipram positron emission tomography in major depressive disorder
    Masahiro Fujita
    Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Maryland 20892 1026, USA
    Biol Psychiatry 72:548-54. 2012
    ..This study sought to quantify the binding of 11C-(R)-rolipram, a PDE4 inhibitor, as an indirect measure of this enzyme's activity in the brain of individuals with major ..
  3. ncbi Differential effects of rolipram on chronic subcutaneous inflammatory angiogenesis and on peritoneal adhesion in mice
    Juliana B Mendes
    Departments of Physiology and Biophysics and General Pathology, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil
    Microvasc Res 78:265-71. 2009
    The specific PDE4 inhibitor (rolipram) has been shown to attenuate excessive accumulation/activation of inflammatory cells and fibroblasts and cytokine production in several pathological conditions through cyclic nucleotide modulation...
  4. ncbi Inhibitor binding to type 4 phosphodiesterase (PDE4) assessed using [3H]piclamilast and [3H]rolipram
    Yu Zhao
    Department of Pharmacology, University of Tennessee Health Science Center, 874 Union Avenue, Memphis, TN 38163, USA
    J Pharmacol Exp Ther 305:565-72. 2003
    Piclamilast is a type 4 phosphodiesterase (PDE4) inhibitor with equal affinity for the high-affinity rolipram binding site (HARBS) and low-affinity rolipram binding site (LARBS)...
  5. pmc Kinetic analysis in human brain of [11C](R)-rolipram, a positron emission tomographic radioligand to image phosphodiesterase 4: a retest study and use of an image-derived input function
    Paolo Zanotti-Fregonara
    Molecular Imaging Branch, National Institute of Mental Health, Bethesda, Maryland 20892 2035, USA
    Neuroimage 54:1903-9. 2011
    11)C](R)-rolipram provides a measure of the density of phosphodiesterase 4 (PDE4) in brain, an enzyme that metabolizes cAMP...
  6. pmc Antidepressant- and anxiolytic-like effects of the phosphodiesterase-4 inhibitor rolipram on behavior depend on cyclic AMP response element binding protein-mediated neurogenesis in the hippocampus
    Yun Feng Li
    Department of Behavioral Medicine and Psychiatry, West Virginia University Health Sciences Center, Morgantown, WV 26506 9137, USA
    Neuropsychopharmacology 34:2404-19. 2009
    ..In this study, chronic administration of rolipram (0.31-1.25 mg/kg, 16-23 days) produced antidepressant- and anxiolytic-like effects on behavior in mice...
  7. ncbi Effects of combining methylprednisolone with rolipram on functional recovery in adult rats following spinal cord injury
    Ying Yin
    Department of Clinical Laboratory Science, Wuxi People s Hospital of Nanjing Medical University, Wuxi, PR China
    Neurochem Int 62:903-12. 2013
    ..The phosphodiesterase 4 (PDE4) inhibitor rolipram has been implicated in promotion of regeneration due to elevating cAMP...
  8. pmc Image-derived input function for human brain using high resolution PET imaging with [C](R)-rolipram and [C]PBR28
    Paolo Zanotti-Fregonara
    Molecular Imaging Branch, National Institute of Mental Health NIMH, National Institutes of Health NIH, Bethesda, Maryland, United States of America
    PLoS ONE 6:e17056. 2011
    ..Three of the methods required arterial blood samples to scale the image-input, and four were blood-free methods...
  9. ncbi Regulation of neurogenesis in adult mouse hippocampus by cAMP and the cAMP response element-binding protein
    Shin Nakagawa
    Division of Molecular Psychiatry, Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, Yale University School of Medicine, New Haven, Connecticut 06508, USA
    J Neurosci 22:3673-82. 2002
    ..Activation of the cAMP cascade by administration of rolipram, an inhibitor of cAMP breakdown, increased the proliferation of newborn cells in adult mouse hippocampus...
  10. ncbi The phosphodiesterase-4 (PDE4) inhibitor rolipram decreases ethanol seeking and consumption in alcohol-preferring Fawn-Hooded rats
    Rui Ting Wen
    National Institute on Drug Dependence, Peking University, Beijing, China
    Alcohol Clin Exp Res 36:2157-67. 2012
    ..Thus, it was of interest to determine whether PDE4 was involved in the regulation of alcohol use and abuse...
  11. ncbi Effects of protein kinase A and G inhibitors on hippocampal cholinergic markers expressions in rolipram- and sildenafil-induced spatial memory improvement
    Ali Hosseini-Sharifabad
    Department of Pharmacology, Faculty of Pharmacy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
    Pharmacol Biochem Behav 101:311-9. 2012
    ..In the present study firstly, rats were evaluated for the effects of different doses of the PDE4 inhibitor rolipram and the PDE5 inhibitor sildenafil on spatial memory consolidation in the water maze task...
  12. pmc Population-based input function and image-derived input function for [¹¹C](R)-rolipram PET imaging: methodology, validation and application to the study of major depressive disorder
    Paolo Zanotti-Fregonara
    Molecular Imaging Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA
    Neuroimage 63:1532-41. 2012
    ..the use of a population-based input function (PBIF) and an image-derived input function (IDIF) for [(11)C](R)-rolipram kinetic analysis, with the goal of reducing - and possibly eliminating - the number of arterial blood samples ..
  13. ncbi Rolipram promotes remyelination possibly via MEK-ERK signal pathway in cuprizone-induced demyelination mouse
    Xiaojia Sun
    Department of Neurology, The First Affiliated Hospital of Harbin Medical University, Ha erbin 150001, China
    Exp Neurol 237:304-11. 2012
    b>Rolipram, a 3'-5'-cyclic adenosine monophosphate (cAMP)-dependent phosphodiesterase 4 (PDE4) inhibitor, has long been studied for its immune modulating effects in the treatment of experimental autoimmune encephalomyelitis (EAE)...
  14. pmc Combination therapy of lovastatin and rolipram provides neuroprotection and promotes neurorepair in inflammatory demyelination model of multiple sclerosis
    Ajaib S Paintlia
    Department of Pediatrics, Medical University of South Carolina, Charleston, South Carolina 29425, USA
    Glia 57:182-93. 2009
    ..the past decade, both in vitro and in vivo studies established that statins (HMG-CoA reductase inhibitors) and rolipram (phosphodiesterase-4 inhibitor; blocks the degradation of intracellular cyclic AMP) can prevent the progression ..
  15. pmc The phosphodiesterase inhibitor rolipram delivered after a spinal cord lesion promotes axonal regeneration and functional recovery
    Elena Nikulina
    Biology Department, Hunter College, City University of New York, New York, NY 10024, USA
    Proc Natl Acad Sci U S A 101:8786-90. 2004
    ..We now show that the phosphodiesterase 4 (PDE4) inhibitor rolipram (which readily crosses the blood-brain barrier) overcomes inhibitors of regeneration in myelin in culture and ..
  16. pmc Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumour necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis
    Fiona E McCann
    The Kennedy Institute of Rheumatology, Imperial College London, 65 Aspenlea Road, London, W6 8LH, UK
    Arthritis Res Ther 12:R107. 2010
    ..We assessed the anti-inflammatory effects of a novel PDE4 inhibitor, apremilast, in human synovial cells from rheumatoid arthritis (RA) patients, as well as two murine models of arthritis...
  17. ncbi Quantification of brain phosphodiesterase 4 in rat with (R)-[11C]Rolipram-PET
    Masahiro Fujita
    Molecular Imaging Branch, National Institute of Mental Health, Building 1, Room B3 10, 1 Center Drive, MSC 0135, Bethesda, MD 20892 0135, USA
    Neuroimage 26:1201-10. 2005
    ..Phosphodiesterase 4 (PDE4) catabolizes the second messenger 3', 5'-cyclic adenosine monophosphate and may play a critical role in brain diseases. Our aim was to quantify PDE4 in rats with positron emission tomography (PET)...
  18. pmc Modulation of the cAMP signaling pathway after traumatic brain injury
    Coleen M Atkins
    Department of Neurological Surgery, University of Miami Miller School of Medicine, Miami, FL 33101, USA
    Exp Neurol 208:145-58. 2007
    ..a phosphodiesterase (PDE) IV inhibitor would improve outcome after TBI, we treated animals intraperitoneally with rolipram (0.3 or 3.0 mg/kg) 30 min prior to TBI, and then once per day for 3 days...
  19. ncbi Genistein, a competitive PDE1-4 inhibitor, may bind on high-affinity rolipram binding sites of brain cell membranes and then induce gastrointestinal adverse effects
    Chung Hong Shih
    Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan
    Eur J Pharmacol 643:113-20. 2010
    ..3 to 13.7 microM. Genistein (3-300 microM) concentration-dependently displaced 2nM [(3)H]-rolipram bound on high-affinity rolipram binding sites of brain cell membranes...
  20. pmc Effects of rolipram on adult rat oligodendrocytes and functional recovery after contusive cervical spinal cord injury
    E Beaumont
    Kentucky Spinal Cord Injury Research Center, School of Medicine, University of Louisville, Louisville, KY 40292, USA
    Neuroscience 163:985-90. 2009
    ..4 (PDE4) subtypes and that their death was attenuated up to 3 days after contusive cervical SCI when rolipram, a specific inhibitor of PDE4, was administered...
  21. ncbi The phosphodiesterase inhibitor rolipram promotes survival of newborn hippocampal neurons after ischemia
    Tsutomu Sasaki
    Department of Cardiovascular Medicine, Division of Stroke Research, Osaka University Graduate School of Medicine, Yamadaoka, Suita City, Osaka, Japan
    Stroke 38:1597-605. 2007
    ..We examined whether treatment of mice with the phosphodiesterase-4 inhibitor rolipram enhances hippocampal neurogenesis after ischemia.
  22. pmc Rolipram-induced elevation of cAMP or chondroitinase ABC breakdown of inhibitory proteoglycans in the extracellular matrix promotes peripheral nerve regeneration
    E Udina
    Division of Physical Medicine and Rehabilitation, Faculty of Medicine and Dentistry, Center for Neurosciences, University of Alberta, Edmonton, Alberta, Canada T6G 2S2
    Exp Neurol 223:143-52. 2010
    ..transected common peroneal (CP) nerve in rats and either elevated cAMP in the axotomized neurons by subcutaneous rolipram, a specific inhibitor of phosphodiesterase IV, and/or promoted degradation of proteoglycans in the distal nerve ..
  23. ncbi Combination of olfactory ensheathing cells with local versus systemic cAMP treatment after a cervical rubrospinal tract injury
    Frederic Bretzner
    ICORD International Collaboration on Repair Discoveries, Blusson Spinal Cord Centre, Department of Zoology, University of British Columbia, Vancouver, British Columbia, Canada
    J Neurosci Res 88:2833-46. 2010
    ..In addition, we assessed a systemic increase of cAMP using the phosphodiesterase inhibitor rolipram. OECs prevented cavity formation, attenuated astrocytic hypertrophy and the retraction of the axotomized ..
  24. ncbi Acute rolipram/thalidomide treatment improves tissue sparing and locomotion after experimental spinal cord injury
    Guido C Koopmans
    Department of Anesthesiology, Academic Hospital Maastricht, Maastricht, 6200 AZ, The Netherlands
    Exp Neurol 216:490-8. 2009
    ..In the present investigation, the ability of rolipram and thalidomide (FDA approved drugs) to reduce secondary tissue degeneration and improve motor function was ..
  25. ncbi PDE4 inhibitors roflumilast and rolipram augment PGE2 inhibition of TGF-{beta}1-stimulated fibroblasts
    Shinsaku Togo
    Pulmonary and Critical Care Medicine, University of Nebraska Medical Center, Omaha, NE 68198 5885, USA
    Am J Physiol Lung Cell Mol Physiol 296:L959-69. 2009
    ..The PDE4 inhibitors roflumilast and rolipram both inhibited fibroblast-mediated contraction of three-dimensional collagen gels and fibroblast chemotaxis ..
  26. ncbi Effects of rolipram on induction of action potential bursts in central snail neurons
    Chia Hsien Lin
    Department of Pharmacology, College of Medicine, National Taiwan University, No 1, Sec 1, Jen Ai Road, Taipei, Taiwan
    Exp Neurol 194:384-92. 2005
    Effects of rolipram, a selective inhibitor of phosphodiesterases (PDE) IV, on induction of action potential bursts were studied pharmacologically on the RP4 central neuron of the giant African snail (Achatina fulica Ferussac)...
  27. ncbi PDE4 inhibition prevents preterm delivery induced by an intrauterine inflammation
    Thomas Schmitz
    Institut National de la Santé et de la Recherche Médicale Unité 767, 4 avenue de l Observatoire, 75270 Paris Cedex 06, France
    J Immunol 178:1115-21. 2007
    ..Selective PDE4 inhibition by rolipram prevented the rise in the proinflammatory cytokines...
  28. ncbi Upregulation of phosphodiesterase-4 in the lung of allergic rats
    Hui Fang Tang
    Schering Plough Research Institute, 2015 Galloping Hill Road, K 15 1600, Kenilworth, NJ 07033, USA
    Am J Respir Crit Care Med 171:823-8. 2005
    ..The increases in pulmonary resistance and IL-4 production were both suppressed by the PDE4-selective inhibitor rolipram or the corticosteroid drug dexamethasone...
  29. ncbi The phosphodiesterase-4 inhibitor rolipram protects from ischemic stroke in mice by reducing blood-brain-barrier damage, inflammation and thrombosis
    Peter Kraft
    University Clinic of Würzburg, Dept of Neurology, Wurzburg, Germany
    Exp Neurol 247:80-90. 2013
    ..b>Rolipram specifically inhibits the enzyme phosphodiesterase (PDE) 4 thereby preventing the inactivation of the ..
  30. ncbi Potential of the rat model of conditioned gaping to detect nausea produced by rolipram, a phosphodiesterase-4 (PDE4) inhibitor
    Erin M Rock
    Department of Psychology, University of Guelph, Guelph, Ontario, Canada N1G 2W1
    Pharmacol Biochem Behav 91:537-41. 2009
    b>Rolipram, a phosphodiesterase-4 (PDE4) inhibitor, is of current interest as a cognitive enhancer and as a treatment for inflammatory diseases...
  31. ncbi Regulation of phosphodiesterase-4 (PDE4) expression in mouse brain by repeated antidepressant treatment: comparison with rolipram
    Daniel Dlaboga
    Department of Behavioral Medicine and Psychiatry, West Virginia University Health Sciences Center, Morgantown, 26506 9128, USA
    Brain Res 1096:104-12. 2006
    ..the effects of repeated treatment with the antidepressants desipramine and fluoxetine or the PDE4 inhibitor rolipram on the expression of PDE4D was compared to that of PDE4A and PDE4B, the other two subtypes expressed in the brain...
  32. ncbi Rolipram, a phosphodiesterase 4 inhibitor, stimulates osteoclast formation by inducing TRANCE expression in mouse calvarial cells
    Eun Sook Cho
    College of Pharmacy, Sookmyung Women s University, Seoul 140 742, Korea
    Arch Pharm Res 27:1258-62. 2004
    Phosphodiesterase (PDE) 4 is an enzyme that degrades intracellular cAMP. In the present study, the effect of rolipram, a specific phosphodiesterase (PDE) 4 inhibitor, on osteoclast formation was investigated...
  33. pmc The therapeutic profile of rolipram, PDE target and mechanism of action as a neuroprotectant following spinal cord injury
    Sandra Marie Schaal
    The Miami Project to Cure Paralysis, University of Miami Miller School of Medicine, Miami, Florida, United States of America
    PLoS ONE 7:e43634. 2012
    ..of cyclic adenosine monophosphate (cyclic AMP), via administration of the phosphodiesterase 4 (PDE4) inhibitor Rolipram. The current study sought to determine the optimal neuroprotective dose, route and therapeutic window for ..
  34. ncbi Rolipram promotes functional recovery after contusive thoracic spinal cord injury in rats
    Luís M Costa
    Department of Veterinary Sciences, CIDESD, University of Tras os Montes e Alto Douro, PO Box 1013, 5001 801 Vila Real, Portugal
    Behav Brain Res 243:66-73. 2013
    ..Elevation of cAMP via the phosphodiesterase 4 (PDE4) inhibitor, rolipram, decreases neuronal sensitivity to myelin inhibitors, increases growth potential and is neuroprotective...
  35. ncbi Protective effects of phosphodiesterase-4-specific inhibitor rolipram on acute ischemia-reperfusion injury in rat kidney
    Emin Mammadov
    Department of Urology, Faculty of Medicine, University of Cukurova, Adana, Turkey
    Urology 80:1390.e1-6. 2012
    To investigate the effect of Rolipram, a phosphodiesterase-4-inhibitor, on renal ischemia-reperfusion injury (IRI) in rats.
  36. pmc Involvement of cyclic AMP systems in morphine physical dependence in mice: prevention of development of morphine dependence by rolipram, a phosphodiesterase 4 inhibitor
    T Mamiya
    Department of Neuropsychopharmacology and Hospital Pharmacy, Nagoya University Graduate School of Medicine, 65 Tsurama-cho, Showa-ku, Nagoya 466-8560, Japan
    Br J Pharmacol 132:1111-7. 2001
    In this study, we examined whether morphine dependence was inhibited by rolipram, a cyclic AMP selective phosphodiesterase inhibitor in mice, since a role for the cyclic AMP systems in the development of morphine dependence has been ..
  37. ncbi The phosphodiesterase 4 inhibitor rolipram protects against cigarette smoke extract-induced apoptosis in human lung fibroblasts
    Jeong Woong Park
    Department of Pulmonary and Critical Care Medicine, Gachon University, Gil Medical Center, 1198 Guwol dong, Namdong gu, Incheon, Republic of Korea
    Eur J Pharmacol 706:76-83. 2013
    ..We investigated the effect of rolipram, a first generation PDE4 inhibitor, on the regulation of cigarette smoke-induced apoptosis...
  38. ncbi SB 207499 (Ariflo), a potent and selective second-generation phosphodiesterase 4 inhibitor: in vitro anti-inflammatory actions
    M S Barnette
    Department of Pulmonary Pharmacology, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania, USA
    J Pharmacol Exp Ther 284:420-6. 1998
    First-generation phosphodiesterase 4 (PDE4) inhibitors, such as rolipram, inhibit the activation of immune and inflammatory cells...
  39. ncbi Beneficial effects of rolipram in a quinolinic acid model of striatal excitotoxicity
    Zena DeMarch
    Laboratory of Neuroanatomy, Santa Lucia Foundation IRCCS at the European Center for Brain Research, Via del Fosso Fiorano 64, 00143 Rome, Italy
    Neurobiol Dis 25:266-73. 2007
    ..The phosphodiesterase type IV inhibitor rolipram increases CREB phosphorylation. Such drug has a protective effect in global ischaemia and embolism in rats...
  40. ncbi Administration of the phosphodiesterase type 4 inhibitor rolipram into the amygdala at a specific time interval after learning increases recognition memory persistence
    Aline Werenicz
    Department of Pharmacology, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil
    Learn Mem 19:495-8. 2012
    Here we show that administration of the phosphodiesterase type 4 (PDE4) inhibitor rolipram into the basolateral complex of the amygdala (BLA) at a specific time interval after training enhances memory consolidation and induces memory ..
  41. ncbi Chemoresistant KM12C colon cancer cells are addicted to low cyclic AMP levels in a phosphodiesterase 4-regulated compartment via effects on phosphoinositide 3-kinase
    David G McEwan
    The Beatson Institute for Cancer Research, Cancer Research UK Beatson Laboratories, Glasgow, United Kingdom
    Cancer Res 67:5248-57. 2007
    ..cyclase activator forskolin together with the specific cyclic AMP (cAMP) phosphodiesterase-4 (PDE4) inhibitor rolipram, but not the cAMP phosphodiesterase-3 (PDE3) inhibitor cilostamide, causes profound growth arrest of ..
  42. pmc The PDE4 inhibitor rolipram prevents NF-kappaB binding activity and proinflammatory cytokine release in human chorionic cells
    Roxane Hervé
    Institut National de la Sante et de la Recherche Medicale, Unité 767, Paris, France
    J Immunol 181:2196-202. 2008
    ..The presence of the PDE4 inhibitor rolipram reduces the TNF-alpha production and the activation of the three NF-kappaB complexes...
  43. ncbi Rolipram attenuates MK-801-induced deficits in latent inhibition
    Jennifer A Davis
    Temple University, Department of Psychology, Philadelphia, PA 19122, USA
    Behav Neurosci 119:595-602. 2005
    ..The authors examine whether amplification of the cAMP signaling pathway by rolipram, a selective Type 4 cAMP phosphodiesterase inhibitor, reverses MK-801-induced impairments in latent inhibition...
  44. ncbi Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram
    Robert X Xu
    Department of Computational, Analytical and Structural Sciences, GlaxoSmithKline, 5 Moore Drive, V 180, Research Triangle Park, NC 27709, USA
    J Mol Biol 337:355-65. 2004
    ..0 A), 8-Br-AMP (2.13 A) and the potent inhibitor rolipram (2.0 A)...
  45. ncbi Inflammation contributes to the postponed ischemic neuronal damage following treatment with a glutamate antagonist in rats
    F Block
    Department of Neurology RWTH Aachen, Pauwelsstrasse 30, D 52057 Aachen, Germany
    Neurosci Lett 298:103-6. 2001
    ..The animals were treated either with NBQX, rolipram, doxycycline or a combination of NBQX and rolipram or doxycycline...
  46. ncbi Rolipram impairs NF-kappaB activity and MMP-9 expression in experimental autoimmune encephalomyelitis
    Antonio J Sanchez
    Neuroimmunology Unit, Universidad Autonoma de Madrid, Hospital Puerta de Hierro, San Martin de Porres 4, 28035, Madrid, Spain
    J Neuroimmunol 168:13-20. 2005
    b>Rolipram suppresses experimental autoimmune encephalomyelitis (EAE) and diminishes cell infiltration of the central nervous system (CNS)...
  47. ncbi A combination immunomodulatory treatment promotes neuroprotection and locomotor recovery after contusion SCI
    Christopher A Iannotti
    Center for Spine Health, Department of Neurological Surgery, Cleveland Clinic, Cleveland, OH 44195, USA
    Exp Neurol 230:3-15. 2011
    ..treatment using (1) selective depletion of peripheral macrophages with liposomal-encapsulated clodronate, and (2) rolipram, a type 4 phosphodiesterase (PDE4) inhibitor, to promote neuroprotection and improve locomotor recovery following ..
  48. pmc Systemic administration of rolipram increases medullary and spinal cAMP and activates a latent respiratory motor pathway after high cervical spinal cord injury
    Satkunendrarajah Kajana
    Department of Anatomy and Cell Biology, Wayne State University School of Medicine, Detroit, Michigan 48201, USA
    J Spinal Cord Med 32:175-82. 2009
    ..Hemisection results in the paralysis of the ipsilateral hemidiaphragm. Chronic administration of rolipram, a specific phosphodiesterase-IV inhibitor, promotes synaptic plasticity and restores phrenic nerve function ..
  49. pmc Activity-based therapies to promote forelimb use after a cervical spinal cord injury
    Haining Dai
    Department of Neuroscience, Georgetown University Medical Center, Washington, DC 20007, USA
    J Neurotrauma 26:1719-32. 2009
    ..A subset of animals received rolipram to promote neuronal plasticity...
  50. doi Curative effects of phosphodiesterase 4 inhibitors cilomilast, roflumilast, and rolipram in dermatitis mouse model
    Daisuke Harada
    J Dermatol Sci 51:215-9. 2008
  51. ncbi Rolipram and SP600125 suppress the early increase in PTP1B expression during cerulein-induced pancreatitis in rats
    Nancy Sarmiento
    Department of Biochemistry, University of Salamanca, Salamanca, Spain
    Pancreas 39:639-45. 2010
    ....
  52. pmc Drug-eluting microfibrous patches for the local delivery of rolipram in spinal cord repair
    Timothy L Downing
    UC Berkeley and UCSF Joint Graduate Program in Bioengineering, Berkeley San Francisco, CA, USA
    J Control Release 161:910-7. 2012
    ..Previous studies have demonstrated that rolipram, an anti-inflammatory and cyclic adenosine monophosphate preserving small molecule, improves spinal cord ..
  53. ncbi Rolipram, a phosphodiesterase type IV inhibitor, exacerbates periventricular white matter lesions in rat pups
    Ying Chao Chang
    Department of Pediatrics, Chang Gung Memorial Hospital, Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung, Taiwan
    Pediatr Res 64:234-9. 2008
    ..We examined whether rolipram, a phosphodiesterase type IV inhibitor, treatment after hypoxic-ischemia is protective against white matter ..
  54. ncbi Inhibition of cAMP degradation improves regulatory T cell-mediated suppression
    Tobias Bopp
    Institute for Immunology, Johannes Gutenberg University, Mainz, Germany
    J Immunol 182:4017-24. 2009
    ..Prevention of cAMP degradation by application of the phosphodiesterase 4 inhibitor rolipram led to strongly increased suppressive potency of nTreg cells for Th2 cells in vitro and in vivo...
  55. ncbi Sub-chronic rolipram treatment leads to a persistent improvement in long-term object memory in rats
    K Rutten
    Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Maastricht University, Universiteitssingel 50, P O Box 616, 6200 MD Maastricht, The Netherlands
    Neurobiol Learn Mem 90:569-75. 2008
    In the present study the effects of sub-chronic rolipram treatment in an object recognition task in 3-month-old male rats were investigated...
  56. ncbi Association between inflammation and nigral neuronal damage following striatal excitotoxic lesion
    F Block
    Department of Neurology, University of Aachen, Pauwelsstr 30, D 52057 Aachen, Germany
    Brain Res 998:29-35. 2004
    ..nigra pars reticulata (SNR) following intrastriatal injection of quinolinic acid (QA) and studied the effect of rolipram, a TNF-alpha-inhibitor, on the secondary neuronal damage...
  57. ncbi Airway relaxant and anti-inflammatory properties of a PDE4 inhibitor with low affinity for the high-affinity rolipram binding site
    Christian Martin
    Division of Pulmonary Pharmacology, Research Centre Borstel, Parkallee 22, 23845 Borstel, Germany
    Naunyn Schmiedebergs Arch Pharmacol 365:284-9. 2002
    ..PDE4 has two binding sites for the archetypal PDE4 inhibitor rolipram, and it has been suggested that binding to the high-affinity rolipram binding site (HARBS) is responsible for the ..
  58. pmc Delayed Nogo receptor therapy improves recovery from spinal cord contusion
    Xingxing Wang
    Program in Cellular Neuroscience, Neurodegeneration and Repair, Yale University School of Medicine, New Haven, CT 06510, USA
    Ann Neurol 60:540-9. 2006
    ..Myelin-associated inhibitors play a role in limiting axonal growth in the adult central nervous system. Blocking these inhibitors may promote neurological recovery from spinal cord contusion...
  59. ncbi Local anti-inflammatory effect and behavioral studies on new PDE4 inhibitors
    Stefano Pieretti
    Department of Drug Research and Evaluation, Italian National Institute of Health, Rome, Italy
    Life Sci 79:791-800. 2006
    ..CC12) reduced the paw edema induced by zymosan in mice as rolipram (the PDE4 inhibitor prototype with anti-inflammatory activity) and indomethacin did...
  60. pmc Maternal exposure to secondhand cigarette smoke primes the lung for induction of phosphodiesterase-4D5 isozyme and exacerbated Th2 responses: rolipram attenuates the airway hyperreactivity and muscarinic receptor expression but not lung inflammation and a
    Shashi P Singh
    Respiratory Immunology Division, Lovelace Respiratory Research Institute, Albuquerque, NM 87108, USA
    J Immunol 183:2115-21. 2009
    ..Interestingly, the PDE4-selective inhibitor rolipram attenuates the increase in AHR, muscarinic receptors, and PDE4D5, but fails to down-regulate lung inflammation, ..
  61. ncbi Rolipram reduces excitotoxic neuronal damage
    F Block
    Department of Neurology RWTH Aachen, Germany
    Neuroreport 12:1507-11. 2001
    ..We examined the effect of rolipram, a TNF-alpha-inhibitor, on excitotoxic neuronal damage...
  62. ncbi Noradrenergic lesions differentially alter the expression of two subtypes of low Km cAMP-sensitive phosphodiesterase type 4 (PDE4A and PDE4B) in rat brain
    S M Farooqui
    Department of Pharmacology and Therapeutics, Louisiana State University Medical Center, Shreveport, LA 71130, USA
    Brain Res 867:52-61. 2000
    ..These data demonstrate that PDE4 subtypes are differentially regulated by presynaptic noradrenergic activity and may play an important role in the maintaining homeostasis of noradrenergic signal transduction in rat brain...
  63. ncbi The flavonoid dioclein reduces the production of pro-inflammatory mediators in vitro by inhibiting PDE4 activity and scavenging reactive oxygen species
    Rodrigo Guabiraba
    Laboratorio de Imunofarmacologia, Departamento de Bioquímica e Imunologia ICB, Universidade Federal de Minas Gerais, Av Antonio Carlos, 6627 Pampulha, 31270 901, Belo Horizonte MG, Brazil
    Eur J Pharmacol 633:85-92. 2010
    ..Murine macrophages were pretreated with dioclein, rolipram, a PDE4 (cyclic nucleotide phosphosdiesterase type 4) inhibitor, or butylated hydroxytoluene (BHT), an ..
  64. pmc Rolipram inhibits leukocyte-endothelial cell interactions in vivo through P- and E-selectin downregulation
    Maria Jesus Sanz
    Department of Pharmacology, Faculty of Medicine, University of Valencia, Spain
    Br J Pharmacol 135:1872-81. 2002
    1. Rolipram, a selective phosphodiesterase (PDE) type 4 inhibitor, was used to characterize leukocyte recruitment mechanisms in models of acute and subacute inflammation...
  65. pmc Inflammation, mucous cell metaplasia, and Bcl-2 expression in response to inhaled lipopolysaccharide aerosol and effect of rolipram
    Kevin R Smith
    COPD Program, Lovelace Respiratory Research Institute, Albuquerque, NM 87108, USA
    Toxicol Appl Pharmacol 253:253-60. 2011
    ..When rats were treated with the phosphodiesterase-4 (PDE4) inhibitor, rolipram (10mg/kg), prior to exposure to aerosolized LPS neutrophil numbers in the BAL were reduced at 8h but not at 24 or ..
  66. ncbi Luteolin, a non-selective competitive inhibitor of phosphodiesterases 1-5, displaced [3H]-rolipram from high-affinity rolipram binding sites and reversed xylazine/ketamine-induced anesthesia
    Ming Chih Yu
    Department of Internal Medicine, Taipei Municipal Wan Fang Hospital, Taiwan
    Eur J Pharmacol 627:269-75. 2010
    ..possible adverse effects, such as nausea, vomiting, and gastric hypersecretion, determined by replacing [(3)H]-rolipram binding and reversing xylazine/ketamine-induced anesthesia...
  67. ncbi Cyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitors
    Ana Castro
    Instituto de Química Médica, Juan de la Cierva 3, 28006 Madrid, Spain
    Med Res Rev 25:229-44. 2005
    ..The review also highlights the novel structural classes of PDE4 and PDE7 inhibitors, and the therapeutic potential that combined PDE4/PDE7 inhibitors offer as immunomodulatory agents...
  68. ncbi Improved sensorimotor function by rolipram following focal cerebral ischemia in rats
    Sonja Hätinen
    Department of Neurology, University of Kuopio, Finland
    Restor Neurol Neurosci 26:493-9. 2008
    b>Rolipram, a specific phosphodiesterase 4 inhibitor (PDE4), is suggested to facilitate functional recovery following brain injury by activation of cAMP/CREB pathway...
  69. ncbi The phosphodiesterase type 4 inhibitor, rolipram, enhances glucocorticoid receptor function
    Andrew H Miller
    Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, 1639 Pierce Dr, Suite 4000, Atlanta, GA 30322, USA
    Neuropsychopharmacology 27:939-48. 2002
    ..Accordingly, we examined GR function in cells treated with rolipram, a phosphodiesterase (PDE) type 4 inhibitor that antagonizes cAMP breakdown...
  70. ncbi Preventive effect of rolipram, a phosphodiesterase 4 enzyme inhibitor, on oxidative renal injury in acute ascending pyelonephritis model in rats
    Sadik Gorur
    Department of Urology, Mustafa Kemal University Faculty of Medicine, Antioch Hatay, Turkey
    Urology 72:743-8. 2008
    To evaluate the effects of rolipram, a phosphodiesterase 4 enzyme inhibitor, on Escherichia coli-induced renal oxidative damage in an acute pyelonephritis (PYN) rat model.
  71. ncbi Effect of phosphodiesterase inhibitor-4, rolipram, on new bone formations by recombinant human bone morphogenetic protein-2
    H Horiuchi
    Department of Orthopaedic Surgery, Shinshu University School of Medicine, Nagano, Japan
    Bone 30:589-93. 2002
    ..Ten or 20 mg/kg per day of Rolipram, a selective inhibitory agent to phosphodiesterase type 4 (PDE-4), or vehicle, was injected subcutaneously into ..
  72. ncbi Localization of phosphorylated cAMP response element-binding protein in immature neurons of adult hippocampus
    Shin Nakagawa
    Division of Molecular Psychiatry, Abraham Ribicoff Research Facilities, Connecticut Mental Health Center, Yale University School of Medicine, New Haven, Connecticut 06508, USA
    J Neurosci 22:9868-76. 2002
    ..These findings indicate that the cAMP-CREB pathway regulates the survival, and possibly the differentiation and function, of newborn neurons...
  73. ncbi Phosphodiesterase inhibitors: a novel mechanism for receptor-independent antipsychotic medications
    C R Maxwell
    Stanley Center for Experimental Therapeutics in Psychiatry, Division of Neuropsychiatry, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA 19104, USA
    Neuroscience 129:101-7. 2004
    ..The current study examines the potential of using non-receptor-based agents that modify intracellular signal transduction as potential antipsychotic medications...
  74. ncbi cAMP and Schwann cells promote axonal growth and functional recovery after spinal cord injury
    Damien D Pearse
    The Miami Project to Cure Paralysis, University of Miami School of Medicine, 1095 NW 14th Terrace, Miami, Florida 33136, USA
    Nat Med 10:610-6. 2004
    ..Inhibition of cAMP hydrolysis by the phosphodiesterase IV inhibitor rolipram prevents this decrease and when combined with Schwann cell grafts promotes significant supraspinal and ..
  75. ncbi Beneficial effects of rolipram in the R6/2 mouse model of Huntington's disease
    Zena DeMarch
    Santa Lucia Foundation IRCCS Hospital at the European Center for Brain Research, Laboratory of Neuroanatomy, Rome, Italy
    Neurobiol Dis 30:375-87. 2008
    We have previously showed that rolipram, a phosphodiesterase type IV inhibitor, displays a neuroprotective effect in a rat quinolinic acid model of HD [DeMarch Z., Giampa C., Patassini S., Martorana A., Bernardi G. and Fusco F.R...
  76. ncbi Attenuation of the activity of the cAMP-specific phosphodiesterase PDE4A5 by interaction with the immunophilin XAP2
    Graeme B Bolger
    Veterans Affairs Medical Center, Huntsman Cancer Institute, Department of Medicine, Division of Oncology, University of Utah Health Sciences Center, Salt Lake City, Utah 84148, USA
    J Biol Chem 278:33351-63. 2003
    ..PDE4A5 to inhibition by the prototypical PDE4 inhibitor 4-[3-(cyclopentyloxy)-4-methoxyphenyl]-2-pyrrolidinone (rolipram) and attenuated the ability of cAMP-dependent protein kinase to phosphorylate PDE4A5 in intact cells...
  77. ncbi Dysregulation of protein kinase a signaling in the aged prefrontal cortex: new strategy for treating age-related cognitive decline
    Brian P Ramos
    Department of Neurobiology, Yale University School of Medicine, New Haven, CT 06510, USA
    Neuron 40:835-45. 2003
    ..These data demonstrate that PKA inhibition, rather than activation, is the appropriate strategy for restoring prefrontal cortical cognitive abilities in the elderly...
  78. pmc Whole-body biodistribution and radiation dosimetry in monkeys and humans of the phosphodiesterase 4 radioligand [(11)C](R)-rolipram: comparison of two-dimensional planar, bisected and quadrisected image analyses
    David R Sprague
    Molecular Imaging Branch, National Institute of Mental Health, Bethesda, MD 20892 2035, USA
    Nucl Med Biol 35:493-500. 2008
    11)C](R)-Rolipram is a selective radioligand for positron emission tomography (PET) imaging of phosphodiesterase 4, an enzyme that metabolizes 3',5'-cyclic adenosine monophosphate...
  79. ncbi PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway
    A Robichaud
    Department of Pharmacology, Merck Frosst Centre for Therapeutic Research, PO Box 1005, Pointe Claire, Dorval, Quebec, Canada H9R 4P8
    Neuropharmacology 40:262-9. 2001
    ..e. 6-(4-pyridylmethyl)-8-(3-nitrophenyl)quinoline, CT-2450 and R-rolipram. It was postulated that PDE4 inhibitors trigger emesis by mimicking the pharmacological actions of alpha(2)-..
  80. ncbi Antidepressant-like profile and reduced sensitivity to rolipram in mice deficient in the PDE4D phosphodiesterase enzyme
    Han Ting Zhang
    Department of Pharmacology, University of Tennessee Health Science Center, Memphis, TN 38163, USA
    Neuropsychopharmacology 27:587-95. 2002
    ..By contrast, the PDE4 inhibitor rolipram only produced antidepressant-like effects in PDE4D+/+ mice...
  81. ncbi Correlation between emetic effect of phosphodiesterase 4 inhibitors and their occupation of the high-affinity rolipram binding site in Suncus murinus brain
    Ryo Hirose
    Pharmaceutical Research Center, Kyowa Hakko Kogyo Co, Ltd, 1188 Shimotogari, Nagaizumi, Shizuoka, 411 8731, Japan
    Eur J Pharmacol 573:93-9. 2007
    We employed an ex vivo [(3)H]rolipram binding experiment to elucidate the mechanism of emetic activity of phosphodiesterase 4 inhibitors...
  82. ncbi Hydrolysis of N-methyl-D-aspartate receptor-stimulated cAMP and cGMP by PDE4 and PDE2 phosphodiesterases in primary neuronal cultures of rat cerebral cortex and hippocampus
    Neesha U Suvarna
    Department of Pharmacology, University of Tennessee Health Science Center, 315 Crowe Building, 974 Union Avenue, Memphis, TN 38163, USA
    J Pharmacol Exp Ther 302:249-56. 2002
    ..However, among the family-selective inhibitors, only the PDE4 inhibitor rolipram enhanced the ability of NMDA to increase cAMP in the neurons...
  83. ncbi Effects of rolipram, a phosphodiesterase 4 inhibitor, in combination with imipramine on depressive behavior, CRE-binding activity and BDNF level in learned helplessness rats
    Tetsuji Itoh
    Department of Drug Safety Evaluation, Developmental Research Laboratories, Shionogi and Co, Ltd, 3 1 1, Futaba cho, Toyonaka, Osaka, 561 0825, Japan
    Eur J Pharmacol 498:135-42. 2004
    ..The present study was undertaken to examine the combination of effects of rolipram, a phosphodiesterase 4 inhibitor, with imipramine, a typical tricyclic antidepressant, on depressive behavior in ..
  84. pmc Rolipram attenuates acute oligodendrocyte death in the adult rat ventrolateral funiculus following contusive cervical spinal cord injury
    Christopher M Whitaker
    Kentucky Spinal Cord Injury Research Center, School of Medicine, University of Louisville, Louisville, KY 40292, USA
    Neurosci Lett 438:200-4. 2008
    b>Rolipram, an inhibitor of phosphodiesterase 4 (PDE4) proteins that hydrolyze cAMP, increases axonal regeneration following spinal cord injury (SCI)...
  85. pmc Rolipram: a specific phosphodiesterase 4 inhibitor with potential antipsychotic activity
    S J Kanes
    Department of Psychiatry and Center for Neurobiology and Behavior, University of Pennsylvania, Philadelphia, PA 19104, USA
    Neuroscience 144:239-46. 2007
    ..To test this hypothesis, we studied the effect of an acute treatment of rolipram, an inhibitor of type 4 phosphodiesterases that degrade cAMP, on acoustic startle and prepulse inhibition (PPI) ..
  86. ncbi Effects of rolipram, pimobendan and zaprinast on ischaemia-induced dysrhythmias and on ventricular cyclic nucleotide content in the anaesthetized rat
    M D Carceles
    University School of Medicine, Department of Anaesthesiology, CSV Arrixaca Hospital, Murcia, Spain
    Eur J Anaesthesiol 20:205-11. 2003
    ..The drugs used were pimobendan, a selective PDE III inhibitor, rolipram, a selective PDE IV inhibitor, and zaprinast, a selective PDE V inhibitor.
  87. ncbi Inhibitory effects of quercetin derivatives on phosphodiesterase isozymes and high-affinity [(3) H]-rolipram binding in guinea pig tissues
    Agnes L F Chan
    Pharmacy Department, Chi Mei Medical Center, 901 Chung Hwa Road, Tainan, 710, Taiwan
    Invest New Drugs 26:417-24. 2008
    b>Rolipram has high (PDE4(H)) and low (PDE4(L)) affinities for phosphodiesterase (PDE)-4, respectively...
  88. ncbi Comparision of the inotropic effects of levosimendan, rolipram, and dobutamine on human atrial trabeculae
    Coskun Usta
    Department of Pharmacology, Akdeniz University, Medical Faculty, Antalya, Turkey
    J Cardiovasc Pharmacol 44:622-5. 2004
    ..compare the positive inotropic effects of 3 different agents with 3 different mechanisms of actions-levosimendan, rolipram, and dobutamine-on human atrial trabecular muscles...
  89. ncbi The type IV phosphodiesterase inhibitor rolipram induces expression of the cell cycle inhibitors p21(Cip1) and p27(Kip1), resulting in growth inhibition, increased differentiation, and subsequent apoptosis of malignant A-172 glioma cells
    Thomas C Chen
    LAC USC Medical Center, Department of Neurosurgery, Pathology, University of Southern California, 1200 N State St, Suite 5046, Los Angeles, CA 90033, USA
    Cancer Biol Ther 1:268-76. 2002
    ..Therefore, we investigated the effects of rolipram, a drug that has undergone clinical trials as an antidepressant and has also been proposed as a treatment for ..
  90. pmc The role of the PDE4D cAMP phosphodiesterase in the regulation of glucagon-like peptide-1 release
    W K Ong
    Strathclyde Institute of Pharmacy, Cell Biology Group, University of Strathclyde, Glasgow, UK
    Br J Pharmacol 157:633-44. 2009
    ..As cAMP is hydrolysed by cAMP phosphodiesterases (PDEs), we determined the role of PDEs and particularly PDE4 in regulating GLP-1 release...
  91. ncbi Early and late bronchoconstrictions, airway hyper-reactivity, leucocyte influx and lung histamine and nitric oxide after inhaled antigen: effects of dexamethasone and rolipram
    T J Toward
    Division of Pharmacology, Welsh School of Pharmacy, Cardiff University, Cardiff, UK
    Clin Exp Allergy 34:91-102. 2004
    ....
  92. pmc Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production: implications for rheumatoid arthritis
    Andrew D Foey
    Kennedy Institute of Rheumatology Division, Charing Cross Hospital Campus, Imperial College School of Medicine, London, UK
    Arthritis Res Ther 5:R317-28. 2003
    ..its slight effect on TNF-alpha results from cAMP being rapidly degraded as the phosphodiesterase IV inhibitor, rolipram, rescues cAMP-dependent activation of cAMP response element binding protein...
  93. ncbi Cellular mechanisms underlying prostaglandin-induced transient cAMP signals near the plasma membrane of HEK-293 cells
    Thomas C Rich
    Department of Pharmacology, College of Medicine and Center for Lung Biology, University of South Alabama, Mobile, AL 36688, USA
    Am J Physiol Cell Physiol 292:C319-31. 2007
    ..Following pretreatment with rolipram (a PDE4 inhibitor), H89 had little or no effect on near-membrane or total cAMP levels...
  94. ncbi Rolipram reverses scopolamine-induced and time-dependent memory deficits in object recognition by different mechanisms of action
    K Rutten
    Department of Psychiatry and Neuropsychology, Brain and Behaviour Institute, Maastricht University, PO Box 616, 6200 MD Maastricht, The Netherlands
    Neurobiol Learn Mem 85:132-8. 2006
    In this study, the effect of the selective phosphodiesterase type 4 (PDE4) inhibitor rolipram on memory performance was investigated using the object recognition task. First, three doses of rolipram (0.01, 0.03 or 0...
  95. ncbi Adenovirus-mediated delivery and expression of a cAMP-dependent protein kinase inhibitor gene to BEAS-2B epithelial cells abolishes the anti-inflammatory effects of rolipram, salbutamol, and prostaglandin E2: a comparison with H-89
    Koremu K Meja
    Thoracic Medicine, National Heart and Lung Institute, Imperial College London, London, United Kingdom
    J Pharmacol Exp Ther 309:833-44. 2004
    ..antagonized MCP-1-induced [(3)H]AA release and enhanced the inhibitory effect of submaximal concentrations of rolipram and 8-bromo-cAMP...
  96. ncbi Difference in preventive effects between the phosphodiesterase iv inhibitor rolipram and anti-arthritic drugs on antigen-induced arthritis in mice
    Kouya Yamaki
    Department of Pharmacology, Kobe Pharmaceutical University, Kobe, Hyogo, Japan
    Immunol Invest 36:131-45. 2007
    The efficacy of the phosphodiesterase (PDE) IV inhibitor rolipram on antigen-induced arthritis (AIA) in mice was evaluated in comparison with clinically used anti-arthritic drugs...
  97. ncbi Elastolytic activity and alveolar epithelial type-1 cell damage after chronic LPS inhalation: effects of dexamethasone and rolipram
    Frederick J Johnson
    Division of Pharmacology, Welsh School of Pharmacy, Cardiff University, King Edward VII Avenue, Cathays Park, Cardiff, CF10 3XF, UK
    Toxicol Appl Pharmacol 207:257-65. 2005
    ..The effect of the corticosteroid, dexamethasone, or the phosphodiesterase-4 (PDE4)-inhibitor, rolipram, on these features was studied...
  98. pmc Characterization of five different proteins produced by alternatively spliced mRNAs from the human cAMP-specific phosphodiesterase PDE4D gene
    G B Bolger
    Department of Veterans Affairs Medical Center, 151M, and Huntsman Cancer Institute, Department of Oncologic Sciences and Department of Medicine Hematology Oncology University of Utah Health Sciences Center, Salt Lake City, UT 84148, USA
    Biochem J 328:539-48. 1997
    ..two isoforms (HSPDE4D4 and HSPDE4A5) encoded by the human PDE4D gene, one of four genes that encode cAMP-specific rolipram-inhibited 3',5'-cyclic nucleotide phosphodiesterases (type IVPDEs; PDE4 family)...
  99. pmc Selective PDE inhibitors rolipram and sildenafil improve object retrieval performance in adult cynomolgus macaques
    K Rutten
    Department of Neuroscience, School for Mental Health and Neuroscience, Maastricht University, Universiteitssingel 50, PO Box 616, 6200 MD Maastricht, The Netherlands
    Psychopharmacology (Berl) 196:643-8. 2008
    ..However, studies evaluating the effects of PDE inhibition on prefrontal cortex-dependent cognition and in monkeys are rare...
  100. ncbi Selective inhibition of purified human phosphodiesterase 4A expressed in yeast cell GL62 by ciclamilast, piclamilast, and rolipram
    Jun Chun Chen
    Respiratory Drugs Research Laboratory of State Food and Drugs Administration of China, Medical School of Zhejiang University, Hangzhou 310031, China
    Acta Pharmacol Sin 25:1171-5. 2004
    ..and investigate the effects of selective phosphodiesterase 4 (PDE4) inhibitors (ciclamilast, piclamilast, and rolipram), selective phosphodiesterase 5 (PDE5) inhibitor zaprinast, and cyclooxygenase (COX) inhibitors (aspirin, ..
  101. ncbi Effects of rolipram, a selective inhibitor of type 4 phosphodiesterase, on lipopolysaccharide-induced uveitis in rats
    Zai Long Chi
    Department of Ophthalmology, Toyama Medical and Pharmaceutical University, Sugitani, Toyama, Japan
    Invest Ophthalmol Vis Sci 45:2497-502. 2004
    To investigate effects of rolipram, an inhibitor of type 4 phosphodiesterase, on lipopolysaccharide (LPS)-induced uveitis in Wistar rats.

Research Grants56

  1. Memory and Mood Enhancing Therapies for Gulf War Illness
    Ashok K Shetty; Fiscal Year: 2013
    ..Indeed, our preliminary studies suggest that administration of antidepressants such as fluoxetine (FLU) or rolipram (ROL) after a combined exposure to chemicals (PB+DEET+Permethrin) and stress has promise for improving the ..
  2. Countermeasures for chlorine-induced airway fibrosis
    Gary W Hoyle; Fiscal Year: 2013
    ..agonists butaprost and iloprost;the long-lasting ss-agonist formoterol and the type 4 phosphodiesterase inhibitor rolipram;stimulation of plasminogen activation with urokinase-type plasminogen activator or the plasminogen activator ..
  3. Regulation of CXCR4 by cognate and non-cognate ligands
    Elias Lolis; Fiscal Year: 2013
    ..in the glioblastoma mouse model required an increase on cAMP and that the cAMP phosphodiesterase inhibitor rolipram had similar therapeutic effects as CXCR4 antagonism due to an increase in cAMP...
  4. Up-regulation of Mucin Gene Transcription-Otitis Media
    Jian dong Li; Fiscal Year: 2013
    ..preliminary studies indicate that MKP-1 itself is further negatively controlled by phosphodiesterase 4B (PDE4B);Rolipram, a specific inhibitor of PDE4 that has been already in late phase III clinical trial for asthma and COPD, ..
  5. Phosphodiesterease-4 (PDE4) as a Novel Target to Reduce Ethanol Consumption
    Han Ting Zhang; Fiscal Year: 2012
    ..This will be accomplished by examining the effect of rolipram, a prototypical inhibitor of PDE4, on ethanol consumption in well recognized animal models of excessive alcohol ..
  6. Device for Delivery of Rolipram to Liver for Treatment of Alcoholic Liver Disease
    Leila Gobejishvili; Fiscal Year: 2012
    ..We propose to develop a carrier system that minimizes release of free-drug while circulating, and concentrates drug in the liver, thereby maximizing the therapeutic effect while minimizing severe side effects. ..
  7. The Role of Cyclic AMP in Alcohol Withdrawal and Mental Disease
    JULIA ANN CHESTER; Fiscal Year: 2010
    ..to explore the therapeutic potential of two promising drugs that raise intracellular cAMP levels, forskolin and rolipram, to reduce physical, cognitive, and emotional signs of alcohol withdrawal in mice...
  8. Modulation of the Cyclic AMP Pathway after Traumatic Brain Injury in Aged Animals
    Coleen M Atkins; Fiscal Year: 2010
    ..Treatment with a phosphodiesterase (PDE) inhibitor, rolipram, to increase cAMP levels improves hippocampal synaptic plasticity and learning in the uninjured aged animal...
  9. Therapeutic Targeting of Intracellular Mechanisms Involved in Glial Scar Formatio
    Damien D Pearse; Fiscal Year: 2013
    ..Recent reports have shown that the phosphodiesterase (PDE) inhibitor Rolipram can reduce astrogliosis and Preliminary Data from our laboratory indicates that there is a chronic induction of ..
  10. Novel Therapies for Chlorine-Induced Lung Injury
    Gary W Hoyle; Fiscal Year: 2013
    ..b>Rolipram, a type 4 phosphodiesterase inhibitor, was shown to stimulate alveolar fluid transport, decrease pulmonary edema, ..
  11. Gene silencing of phosphodiesterase-4D (PDE4D) as a therapeutic approach to beta
    Han Ting Zhang; Fiscal Year: 2009
    ..Primarily through this mechanism, the PDE4 inhibitor rolipram not only counteracts the inhibitory effects of high levels of amyloid-beta peptide (Abeta) on cAMP signaling and ..
  12. Phosphodiesterase 4 Subtype Selective Modulators for Psychiatric Disease
    Mark E Gurney; Fiscal Year: 2012
    ..PDE4D modulators have greatly improved tolerability than earlier compounds such as rolipram. Rolipram previously was shown to have anti-depressant activity in human Phase II clinical trials but was poorly ..
  13. Axon Regenration: Synergistic Actions of the MAPK and Cyclic AMP Pathways
    Damien D Pearse; Fiscal Year: 2010
    ..a one-time injection of cAMP into the cord above and below the implant, and a two-week subcutaneous infusion of Rolipram induced substantial growth of serotonergic fibers into the implant and beyond into the cord caudal to the implant...
  14. Effects of Lead on Cortical Development and Plasticity
    MARY A WILSON; Fiscal Year: 2010
    ..be blocked by the NMDA antagonist dextromethorphan, inhibition of Ras with FPT III, or inhibition of PDE4 with rolipram, 3) to determine whether postnatal lead exposure increases or decreases phosphorylation of CREB, ERK1/2 or CaMKIV ..
  15. CYCLIC NUCLEOTIDE PHOSPHODIESTERASE IN ASTROGLIA
    VERGINE MADELIAN; Fiscal Year: 1992
    ..One of the PDE types is selectively inhibited by RO 20-1724 and Rolipram. Rolipram has been effectively used in treating major (DMS-III) and endogenous (ICD-9) depressions, suggesting ..
  16. Phosphodiesterase-inhibitors, vascular integrity and SCI
    Raymond J Grill; Fiscal Year: 2010
    ..We propose to determine whether acute treatment with 2 PDE-ls, a specific PDE4a-inhibitor called rolipram and a non- selective PDE-I known as pentoxifylline reduce protein extravasation following SCI;protecting the BSCB ..
  17. Novel A2A Adenosine Agonists in Vascular Protection
    Jayson Rieger; Fiscal Year: 2005
    ..combined used of two synergistic anti-inflammatory compounds, ATL146e, an agonist of A2A adenosine receptors, and rolipram, a type IV phosphodiesterase (PDE) inhibitor, loaded into a proprietary nanoporous stent coating, inhibits stent ..
  18. APOPTOSIS IN NORMAL AND MALIGNANT LYMPHOCYTES
    Adam Lerner; Fiscal Year: 2003
    ..CLL cells contained PDE4B transcript, protein and enzymatic activity. Inhibition of PDE4 by rolipram raised cAMP levels and induced apoptosis in CLL cells in a dose dependent fashion that required 48 hours to ..
  19. Exploring the role of Phosphodiesterase 4A in axonal regeneration
    Benjamin Sachs; Fiscal Year: 2007
    ..Indeed, rolipram, an inhibitor of type four phosphodiesterases (PDE4s), the enzymes responsible for cAMP degradation, has been ..
  20. Cyclic AMP-mediated apoptosis in lymphoid malignancies
    Adam Lerner; Fiscal Year: 2009
    Inhibitors of type 4 cAMP phosphodiesterase (PDE4) such as rolipram-induced apoptosis in B cell chronic lymphocytic leukemia, even in the absence of exogenous pharmacologic agents that activate adenylate cyclase such as the diterpene ..
  21. NEUROPSYCHOPHARMACOLOGY OF CYCLIC AMP PDE INHIBITORS
    JAMES O DONNELL; Fiscal Year: 2007
    Inhibitors of Type 4 cyclic AMP phosphodiesterase (PDE4), such as rolipram, produce both antidepressant-like and memory-enhancing effects in preclinical models...
  22. EFFICIENT SYNTHESIS OF BIOACTIVE GAMMA LACTAMS
    KYUNG JUNG; Fiscal Year: 2005
    ..Our synthetic targets encompass lactacystin, pramanicin, statine, rolipram, epolactaene, and kainic acid...
  23. MICROVESSEL PERMEABILITY AND TUMOR METASTASIS
    Bingmei Fu; Fiscal Year: 2000
    ..In specific aim 3, the effect of 8 bromo-cAMP and agents that increase cAMP such as forskolin or rolipram on VEGF induces hyperpermeability will be examined...
  24. Pathology and Biology of Neurodegenerative Disease
    Michael Shelanski; Fiscal Year: 2007
    DESCRIPTION (provided by applicant): The demonstration that the drugs rolipram and forskalin reverse the inhibition of LTP induced by alpha beta in hippocampal slices and that exposure of cultured hippocampal neurons to alpha beta causes ..
  25. SEXUAL DIFFERENTIATION OF MOUSE VOMERONASAL FUNCTION
    James Cherry; Fiscal Year: 2004
    ....
  26. Dopamine D4 Receptor in Sustained Attention
    Kehong Zhang; Fiscal Year: 2003
    ..The findings may also provide a pharmacological basis for innovative treatment for ADHD to replace stimulant therapy. ..
  27. Store Operated Calcium Entry: Lung Endothelial Permeability
    Troy Stevens; Fiscal Year: 2009
    ....
  28. PDE3 Inhibitors: Selective Blockers of Oocyte Maturation
    Jeffrey Jensen; Fiscal Year: 2007
    ..This approach is expected to provide a foundation for future Phase 1 trials of PDE3 inhibitors in humans. ..
  29. Neuroimmune Mechanisms of Glucocorticoid Resistance
    Andrew H Miller; Fiscal Year: 2010
    ..Taken together, these studies will help identify novel targets for the treatment of mood disorders in both medically ill and medically healthy patients. ..
  30. TRPV4 Initiates Ventilator Induced Lung Injury
    James C Parker; Fiscal Year: 2010
    ..and that lung PAR1 and PAR2 activation peptidesincrease lung vascular permeability in TRPV4+/+ mice ventilated with high airway pressures but not in TRPV4-/- mice, or either genotype ventilated with low airway pressures ..
  31. ADENOSINE AND RENAL INJURY
    MARK OKUSA; Fiscal Year: 2009
    ..These experiments also will shed light on the role of inflammation in the etiology of DN and provide insights into other potential anti-inflammatory therapeutic strategies. ..
  32. cAMP Phosphodiesterase and Lung Endothelial Cell Permeability
    Thomas C Rich; Fiscal Year: 2010
    ..Here we propose to determine whether pharmacological and molecular inhibitors of a specific protein, phosphodiesterase type 7, prevent increases in endothelial permeability in these arteries, and hence, make breathing easier. ..
  33. ADRENAL STEROID--IMMUNE INTERACTIONS
    Andrew Miller; Fiscal Year: 2003
    ..Further understanding of neuroendocrine- immune interactions in viral infections will provide the foundation for developing new therapeutic strategies to limit the immunologic and behavioral morbidity of viral diseases. ..
  34. Conference on Childhood, Culture, and Neurodevelopment
    Mark Barad; Fiscal Year: 2008
    ..abstract_text> ..
  35. HIV/AIDS CLINICAL RESEARCH TRAINING PROGRAM
    Andrew Miller; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  36. Central betal adrenergic receptors and behavior
    Han Ting Zhang; Fiscal Year: 2004
    ..This will lead to the better understanding of pathophysiology and pharmacotherapy of depression. ..
  37. Rodent models of anxiety disorder treatment
    Mark Barad; Fiscal Year: 2004
    ..abstract_text> ..
  38. Determinants of Pulmonary Endothelial Cell Function Conf
    Troy Stevens; Fiscal Year: 2004
    ..At the conclusion of this meeting and as part of the published report, we will have identified areas of need for future investigation in lung vascular biology. ..
  39. SOLUTE AND FLUID TRANSPORT ACROSS THE CONJUNCTIVA
    OSCAR CANDIA; Fiscal Year: 2002
    ..Based on this model, he will devise protocols to modify and possibly reverse the secretory/absorptive properties of the tissue. ..
  40. REGULATION OF THE CAMP SPECIFIC PHOSPHODIESTERASES
    Graeme Bolger; Fiscal Year: 2003
    ..5. The two-hybrid system will be used to clone cDNAs encoding proteins that interact with 4 novel PDE4 isoforms. ..
  41. IFN ALPHA-INDUCED DEPRESSION
    Andrew Miller; Fiscal Year: 2003
    ....
  42. ADRENAL STEROID-IMMUNE INTERACTIONS IN VIRAL INFECTIONS
    Andrew Miller; Fiscal Year: 2002
    ..Taken together, these studies will provide the foundation for developing new treatment strategies for immunomodulation drawing upon advances in neuroendocrinology and the neurosciences. ..
  43. AIRWAY PERFUSION ASSISTED LIQUID VENTILATOR
    James Parker; Fiscal Year: 2002
    ..Other applications include continuous intrapulmonary administration of drugs and anesthetics and clearance of material from the lungs...
  44. CA++ INHIBITION OF CAMP IN LUNG ENDOTHELIAL PERMEABILITY
    Troy Stevens; Fiscal Year: 2001
    ..It is hoped completion of these studies will improve our understanding of mechanisms which regulate endothelial barrier properties so that effective therapies can be developed for treatment of non-cardiogenic pulmonary edema. ..
  45. Molecular Mechanisms of PDE5 Regulation
    Jackie Corbin; Fiscal Year: 2005
    ..Results of these studies will provide a basis for understanding fundamental questions relating to cGMP signaling in many tissues. ..
  46. Measurement of Fluid Flow Across the Ocular Ciliary Body
    OSCAR CANDIA; Fiscal Year: 2006
    ..abstract_text> ..
  47. Pathophysiology of IFN-alpha-induced Sleep Disturbances
    Andrew Miller; Fiscal Year: 2008
    ..Moreover, this work will identify novel targets for the development of treatment strategies for sleep alterations in medically ill patients. ..
  48. Pathology and Treatment of Cytokine-Induced Depression
    Andrew Miller; Fiscal Year: 2008
    ..abstract_text> ..
  49. Fronto-Striatal Dysfunction in IFNa-Induced Depression
    Andrew Miller; Fiscal Year: 2008
    ..abstract_text> ..
  50. Fluid Movement across Conjunctiva: Stimulation and Regulation
    OSCAR CANDIA; Fiscal Year: 2007
    ..These studies may provide the groundwork for the design of future treatment modalities for dry-eye syndromes. ..
  51. Lysophosphatidic Acid Receptors and Acute Renal Failure
    MARK OKUSA; Fiscal Year: 2007
    ..Furthermore, these studies will provide the foundation for future human clinical trials of acute renal failure and renal allograft preservation. ..
  52. Molecular Control of cGMP Signaling by PKGs and PDEs
    Jackie Corbin; Fiscal Year: 2007
    ..A thorough physical and biochemical characterization of PDE11 will be carded out, and the likelihood of regulation of this enzyme by ligand binding to its GAF domains or by enzyme phosphorylation will be explored. ..
  53. Pathogenesis of HIVAN: the role of Nef
    JOHN HE; Fiscal Year: 2007
    ..These studies should elucidate essential mechanism responsible for the development of HIV-associated nephropathy and how Nef plays a role in this pathologic process. ..
  54. Cyclic AMP signaling in cardiac myocytes
    THOMAS RICH; Fiscal Year: 2007
    ..g., protenoid, beta1-,or beta2-adrenergic receptors) or inhibit phosphodiesterase (PDE) will shed new light on the physiologic functions of these enzymes and their relation to cardiac function. ..
  55. Translating Extinction of Fear to Anxiety Disorder Treatment
    Mark Barad; Fiscal Year: 2006
    ..These experiments should help establish the translational validity of the extinction model for anxiety disorder treatment and also may yield potential improvements in current anxiety disorder treatments. ..
  56. Mechanical Injury to Lung Endothelium
    James Parker; Fiscal Year: 2001
    ....